2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. FXR

FXR

FXR; NR1H4

FXR

Related Products

PDF 0.6 MB

Farnesoid X receptor (FXR) is a ligand-activated transcription factor belonging to the nuclear receptor superfamily. FXR regulates the expression of various genes by binding to DNA either as a monomer or a heterodimer with the common partner for NRs, retinoid x receptor (RXR), to FXR response elements. Two known FXR genes exist, the FXRα and FXRβ.

FXR is mainly expressed in liver and small intestine, where it plays an important role in bile acid, lipid, and glucose metabolism. FXR affects several metabolic pathways through its specific target genes, regulating bile acid (BA) synthesis and homeostasis, glucose and lipid metabolism, also exhibiting a crucial role in intestinal bacterial growth and liver regeneration.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-135399A
    Tauro-obeticholic acid sodium
    		Agonist
    Tauro-obeticholic acid sodium is an active metabolite of Obeticholic acid (HY-12222). Obeticholic acid is a potent, selective and orally active FXR agonist.
    Tauro-obeticholic acid sodium
  • HY-103704R
    LY2562175 (Standard)
    		Agonist
    LY2562175 (Standard) is the analytical standard of LY2562175 (HY-103704). This product is intended for research and analytical applications. LY2562175 is a potent and selective FXR agonist, with an EC50 of 193 nM.
    LY2562175 (Standard)
  • HY-107418R
    Tropifexor (Standard)
    		Agonist
    Tropifexor (Standard) is the analytical standard of Tropifexor (HY-107418). This product is intended for research and analytical applications. Tropifexor (LJN452) is a highly potent agonist of FXR with an EC50 of 0.2 nM.
    Tropifexor (Standard)
  • HY-W756134
    Chenodeoxycholic acid 24-acyl-β-D-glucuronide-d5 sodium
    Chenodeoxycholic acid 24-acyl-β-D-glucuronide-d5 sodium is the deuterium labeled Chenodeoxycholic acid 24-acyl-β-D-glucuronide sodium. Chenodeoxycholic acid 24-acyl-β-D-glucuronide sodium is a metabolite of Chenodeoxycholic Acid (HY-76847).
    Chenodeoxycholic acid 24-acyl-β-D-glucuronide-d<sub>5</sub> sodium
  • HY-P1624S
    Teduglutide-Ala(13C3,15N) sodium
    Teduglutide-Ala(13C3,15N) (ALX-0600-Ala(13C3,15N)) sodium is the 13C- and 15N-labeled Teduglutide (HY-P1624). Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis.
    Teduglutide-Ala(<sup>13</sup>C<sub>3</sub>,<sup>15</sup>N) sodium
  • HY-76847S4
    Chenodeoxycholic acid-d2
    		Activator
    Chenodeoxycholic acid-d2 (CDCA-d2) is deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.
    Chenodeoxycholic acid-d<sub>2</sub>
  • HY-133890AS
    Tauro-α-muricholic acid-d4 sodium
    		Antagonist
    Tauro-α-muricholic acid-d4 (sodium) is the deuterium labeled Tauro-α-muricholic acid sodium (HY-133890A). Tauro-α-muricholic acid sodium (T-α-MCA sodium) is a Taurine (HY-B0351)-conjugated primary Bile acid. Tauro-α-muricholic acid sodium is a FXR antagonist with an IC50 of  28 µM. Tauro-α-muricholic acid sodium attenuates other bile acid-activated FXR signaling. Tauro-α-muricholic acid sodium can be used in the research of Alzheimer's disease, glucose metabolism, and lipid metabolism.
    Tauro-α-muricholic acid-d<sub>4</sub> sodium
  • HY-10626R
    T0901317 (Standard)
    		Agonist
    T0901317 (Standard) is the analytical standard of T0901317. This product is intended for research and analytical applications. T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα. T0901317 activates FXR with an EC50 of 5 μM. T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively. T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice.
    T0901317 (Standard)
  • HY-N9933S
    Tauro-β-muricholic acid-d4-1 sodium
    		Antagonist
    Tauro-β-muricholic acid-d4-1 (T-βMCA-d4-1) sodium is the deuterium labeled Tauro-β-muricholic acid (HY-N9933).
    Tauro-β-muricholic acid-d<sub>4</sub>-1 sodium
  • HY-121153
    Altenusin
    		Agonist
    Altenusin shows markedly DPPH radical scavenging activities.
    Altenusin
  • HY-N0468R
    Rebaudioside D (Standard)
    		Activator
    Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research.
    Rebaudioside D (Standard)
  • HY-12365S2
    Tauro-obeticholic acid-d5
    		Agonist
    Tauro-obeticholic acid-d5 is deuterium labeled Tauro-obeticholic acid (HY-135399). Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist.
    Tauro-obeticholic acid-d<sub>5</sub>
  • HY-50911R
    Turofexorate isopropyl (Standard)
    		Agonist
    Turofexorate isopropyl (Standard) is the analytical standard of Turofexorate isopropyl. This product is intended for research and analytical applications. Turofexorate isopropyl (FXR-450) is a potent, selective, and orally bioavailable FXR agonist with EC50 of 4 nM.
    Turofexorate isopropyl (Standard)
  • HY-182395
    DM175
    		Agonist
    DM175 is a partial agonist of FXR. DM175 binds to the ligand-binding domain of FXR and induces the outward movement of Trp454.
    DM175
  • HY-168629
    FXR agonist 9
    		Inhibitor
    FXR agonist 9 (compound 26) is an oral active and selectivity FXR partial agonist with the EC50 of 0.09 µM (75.13 % maximum efficacy). FXR agonist 9 ameliorates pathological features in HFD and CCl4(HY-Y0298)-induced metabolic dysfunction-associated steatohepatitis mice.
    FXR agonist 9
  • HY-10912R
    Fexaramine (Standard)
    		Agonist
    Fexaramine (Standard) is the analytical standard of Fexaramine. This product is intended for research and analytical applications. Fexaramine is a potent and selective FXR agonist with an EC50 of 25 nM. Fexaramine has no activity against hRXRα, hPPARαγδ, mPXR, hPXR, hLXRα, hTRβ, hRARβ, mCAR, mERRγ, and hVDR receptors.
    Fexaramine (Standard)
  • HY-163072
    FXR antagonist 3
    		Antagonist
    FXR antagonist 3 (V02-8) is an intestine-specific farnesoid X receptor (FXR) antagonist, with an IC50 of 0.89 μM.
    FXR antagonist 3
Cat. No. Product Name / Synonyms Application Reactivity